search
Back to results

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

Primary Purpose

Interstitial Cystitis, Bladder Pain Syndrome

Status
Recruiting
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
VNX001
Placebo
Lidocaine
Heparin
Sponsored by
Vaneltix Pharma, Inc.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Interstitial Cystitis focused on measuring interstitial cystitis (IC), bladder pain syndrome (BPS), alkalinized lidocaine, heparin, intravesical, VNX001

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Be able and willing to give a signed informed consent and to follow study instructions Be male or female, ≥ 18 years of age Have moderate-to-severe symptoms of bladder pain of bladder origin for at least 9 months prior to the study May or may not have received a cystoscopy in association with their diagnosis of interstitial cystitis/bladder pain syndrome prior to or at time of screening Have a score of ≥ 16 and ≤ 30 on the Pelvic Pain and Urgency/Frequency (PUF) questionnaire, completed at screening Have moderate to severe pain: a minimum score of 5 is required on the 11-point bladder pain NRS at time of screening and 15 minutes post void immediately prior to study drug administration. Have previously received with positive response, therapeutic intravesicular anesthetic treatments according to medication history Exclusion Criteria: For females, have a positive pregnancy test at screening or be pregnant or lactating Males who are sexually active with females and are not willing to commit to an acceptable method of birth control for the duration of the Postmenopausal women who, if taking hormone replacement therapy, have not been stabilized on a regimen of hormone replacement therapy within 3 months of screening Have a known hypersensitivity to heparin or lidocaine Have used any local anesthetic by any route within 48-hours prior to study drug administration, or used a lidocaine patch or lidocaine containing topical compounds within 14 days prior to study drug administration Have used a tricyclic antidepressant, or a gamma-aminobutyric acid (GABA) analogue (gabapentin or pregabalin), unless taking a stable dose of the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day Have used any pain medication within 6 hours prior to study drug administration Have used narcotics or medical marijuana ≤ 3 weeks prior to study entry Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results Have a known abnormal laboratory test value that, in the investigator's judgement, is clinically significant. Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage) Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain Have any of the following central nervous system (CNS) conditions that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results, severe diagnosed: major depressive disorder, bipolar disorder, schizophrenia, general anxiety disorder, attention deficit disorder, obsessive compulsive disorder, or other major central nervous system disorder Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results Had bladder instillation therapy within 7 days prior to study entry or had a prior bladder instillation with heparin and lidocaine and did not respond Had an in-office cystoscopy within 7 days of study drug administration Had dilatation (hydrodistension) of bladder within 3 months of study entry Evidence or suspected presence of cancer detected during cystoscopy 7 days prior to or at time of initial screening (cystoscopy is not required for entry into the study) Has received any investigational drug or device within 30 days prior to screening Is currently enrolled in another investigational drug or device study Is unwilling or unable to abide by the requirements of the study Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization Are taking any of the following medications, which are inducers of CYP1A2 and/or CYP3A4: Phenytoin, Carbamazepine, St. John's Wort, Phenobarbital, Rifampin Have had any of the following: Bacterial cystitis within 30 days as demonstrated by a positive urine culture (≥ 105 bacteria per mL) History of pelvic irradiation or radiation cystitis History or presence of uterine, cervical, pelvic, rectal, ovarian, or vaginal cancer History of benign or malignant bladder tumors Current chemotherapy History or presence of tuberculous cystitis History or presence of chemical cystitis, including that due to cyclophosphamide History or presence of urinary schistosomiasis Bladder or ureteral calculi Clinically significant infectious vaginitis Currently uncontrolled genital herpes History or presence of urethral diverticulum Presence of bladder fistulae History of ketamine use

Sites / Locations

  • IC Study LLCRecruiting
  • University of California Los Angeles Center for Women's Pelvic Health
  • The Continence Center Medical Group, Inc dba Southern California Continence Center
  • University of California San Diego Medical Center
  • Scripps Clinic Carmel Valley
  • Prestige Medical GroupRecruiting
  • Georgia UrologyRecruiting
  • Southern Clinical Research Associates LLCRecruiting
  • Boston Urogynecology Associates
  • Northwell Health

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Placebo Comparator

Experimental

Experimental

Arm Label

VNX001

Placebo

Lidocaine

Heparin

Arm Description

VNX001 (lidocaine HCl [200 mg] and heparin sodium [50,000 USPU] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)

Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)

Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)

Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)

Outcomes

Primary Outcome Measures

Sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12)
A measure of the sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.

Secondary Outcome Measures

Sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively)
A measure of the sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose
Average absolute change and average percentage change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose, as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Change in Question 3 of the Patient Overall Rating of Improvement of Symptoms (PORIS) questionnaire
Percentage of subjects achieving ≥ 50% improvement in Question 3 of the PORIS questionnaire at 1, 10, and 24 hours post-dose. The PORIS questionnaire is an assessment of the subject's condition after treatment compared to before treatment. In particular, Question 3 of the PORIS questionnaire asks subjects to select the category that best describes the overall change in their condition compared to before receiving study medication; the choices are: worse, no better (0% improvement), slightly improved (25% improvement), moderately improved (50% improvement), greatly improved (75% improvement), or symptoms gone (100% improvement).
Use of optional open-label intravesical administration of VNX001
Number of patients requesting the optional open-label intravesical administration of VNX001 at 24-48 hours after randomized study drug administration
Adverse events (AEs)
Incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and discontinuations due to AEs

Full Information

First Posted
February 10, 2023
Last Updated
May 25, 2023
Sponsor
Vaneltix Pharma, Inc.
Collaborators
Prevail Infoworks, Inc
search

1. Study Identification

Unique Protocol Identification Number
NCT05737121
Brief Title
Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS
Official Title
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Multi-Center Single Dose Study to Evaluate the Safety and Effectiveness of VNX001 Compared to Placebo, the Individual Components of Lidocaine, and Heparin in Subjects With Interstitial Cystitis/Bladder Pain Syndrome
Study Type
Interventional

2. Study Status

Record Verification Date
May 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 22, 2023 (Actual)
Primary Completion Date
May 22, 2024 (Anticipated)
Study Completion Date
May 22, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vaneltix Pharma, Inc.
Collaborators
Prevail Infoworks, Inc

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride (HCl)) for the reduction of bladder pain in patients with interstitial cystitis (IC) / bladder pain syndrome (BPS).
Detailed Description
This is a Phase 2, prospective, randomized, double-blind, placebo-controlled, multi-center, single-dose, pharmacodynamic study designed to evaluate the efficacy and safety of the combination product (VNX001) versus placebo and its individual components (heparin sodium and lidocaine hydrochloride) for the reduction of bladder pain in patients with IC/BPS. The study will enroll a target of 120 subjects, with a maximum of 180 subjects, across approximately 12 sites in the United States. Each study subject will receive a single dose of VNX001, placebo (alkalinized phosphate buffer), alkalinized lidocaine, or alkalinized heparin by random assignment. The randomization ratio will be 3:1:3:1, respectively. At 24-48-hours post-dose, all subjects will be given the option of requesting a single dose of VNX001.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Interstitial Cystitis, Bladder Pain Syndrome
Keywords
interstitial cystitis (IC), bladder pain syndrome (BPS), alkalinized lidocaine, heparin, intravesical, VNX001

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Model Description
IC/BPS patients will be randomly assigned to receive a single dose of one of the following treatments in a ratio of 3:1:3:1: VNX001 (n=45): alkalinized buffered lidocaine HCl (200 mg) and heparin sodium (50,000 USPU), administered as an intravesical instillation Placebo (n=15): alkalinized buffer, administered as an intravesical instillation Lidocaine (n=45): alkalinized buffered lidocaine HCl (200 mg), administered as an intravesical instillation Heparin (n=15): alkalinized buffered heparin sodium (50,000 USPU), administered as an intravesical instillation At 24-48-hours post-dose, all subjects will be given the option of requesting a single open-label dose of VNX001.
Masking
ParticipantInvestigator
Masking Description
Double-blind
Allocation
Randomized
Enrollment
120 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
VNX001
Arm Type
Experimental
Arm Description
VNX001 (lidocaine HCl [200 mg] and heparin sodium [50,000 USPU] in alkalinized buffer), administered as a single dose via intravesical instillation; n=45 (anticipated)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
Arm Title
Lidocaine
Arm Type
Experimental
Arm Description
Lidocaine HCl (200 mg) in alkalinized buffer, administered as a single dose via intravesical instillation; n=45 (anticipated)
Arm Title
Heparin
Arm Type
Experimental
Arm Description
Heparin sodium (50,000 USPU) in alkalinized buffer, administered as a single dose via intravesical instillation; n=15 (anticipated)
Intervention Type
Drug
Intervention Name(s)
VNX001
Other Intervention Name(s)
Alkalinized lidocaine HCl and heparin sodium
Intervention Description
VNX001 (alkalinized lidocaine HCl and heparin sodium)
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
Placebo (for VNX001)
Intervention Description
Inactive placebo for VNX001
Intervention Type
Drug
Intervention Name(s)
Lidocaine
Other Intervention Name(s)
Alkalinized lidocaine HCl
Intervention Description
Alkalinized lidocaine hydrochloride
Intervention Type
Drug
Intervention Name(s)
Heparin
Other Intervention Name(s)
Alkalinized heparin sodium
Intervention Description
Alkalinized heparin sodium
Primary Outcome Measure Information:
Title
Sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12)
Description
A measure of the sum of bladder pain intensity differences from baseline to 12 hours post-dose (SPID-12), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Time Frame
12 hours
Secondary Outcome Measure Information:
Title
Sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively)
Description
A measure of the sum of bladder pain intensity differences from baseline to 6, 10, and 24 hours post-dose (SPID-6, SPID-10, and SPID-24, respectively), as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Time Frame
6, 10, or 24 hours
Title
Change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose
Description
Average absolute change and average percentage change in bladder pain from baseline to 1, 4, 8, 12, and 24 hours post-dose, as determined using an 11-point numerical rating scale (NRS) for bladder pain. The 11-point NRS for bladder pain is a scale from 0 to 10, with 0 indicating no bladder pain and 10 indicating the worst imaginable bladder pain.
Time Frame
1, 4, 8, 12, and 24 hours
Title
Change in Question 3 of the Patient Overall Rating of Improvement of Symptoms (PORIS) questionnaire
Description
Percentage of subjects achieving ≥ 50% improvement in Question 3 of the PORIS questionnaire at 1, 10, and 24 hours post-dose. The PORIS questionnaire is an assessment of the subject's condition after treatment compared to before treatment. In particular, Question 3 of the PORIS questionnaire asks subjects to select the category that best describes the overall change in their condition compared to before receiving study medication; the choices are: worse, no better (0% improvement), slightly improved (25% improvement), moderately improved (50% improvement), greatly improved (75% improvement), or symptoms gone (100% improvement).
Time Frame
1, 10, and 24 hours
Title
Use of optional open-label intravesical administration of VNX001
Description
Number of patients requesting the optional open-label intravesical administration of VNX001 at 24-48 hours after randomized study drug administration
Time Frame
48 hours
Title
Adverse events (AEs)
Description
Incidence of treatment-emergent adverse events (TEAEs), drug-related adverse events (AEs), and discontinuations due to AEs
Time Frame
72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Be able and willing to give a signed informed consent and to follow study instructions Be male or female, ≥ 18 years of age Have moderate-to-severe symptoms of bladder pain of bladder origin for at least 9 months prior to the study May or may not have received a cystoscopy in association with their diagnosis of interstitial cystitis/bladder pain syndrome prior to or at time of screening Have a score of ≥ 16 and ≤ 30 on the Pelvic Pain and Urgency/Frequency (PUF) questionnaire, completed at screening Have moderate to severe pain: a minimum score of 5 is required on the 11-point bladder pain NRS at time of screening and 15 minutes post void immediately prior to study drug administration. Have previously received with positive response, therapeutic intravesicular anesthetic treatments according to medication history Exclusion Criteria: For females, have a positive pregnancy test at screening or be pregnant or lactating Males who are sexually active with females and are not willing to commit to an acceptable method of birth control for the duration of the Postmenopausal women who, if taking hormone replacement therapy, have not been stabilized on a regimen of hormone replacement therapy within 3 months of screening Have a known hypersensitivity to heparin or lidocaine Have used any local anesthetic by any route within 48-hours prior to study drug administration, or used a lidocaine patch or lidocaine containing topical compounds within 14 days prior to study drug administration Have used a tricyclic antidepressant, or a gamma-aminobutyric acid (GABA) analogue (gabapentin or pregabalin), unless taking a stable dose of the medication for ≥ 3 weeks. The stable dose of gabapentin may not exceed 1,200 mg per day, and the stable dose of pregabalin may not exceed 150 mg per day Have used any pain medication within 6 hours prior to study drug administration Have used narcotics or medical marijuana ≤ 3 weeks prior to study entry Have used prohibited drugs as determined by self-report, positive urine drug screen, or in the opinion of the investigator be under the influence of drugs affecting mentation precluding their ability to follow the study protocol or bias study results Have a known abnormal laboratory test value that, in the investigator's judgement, is clinically significant. Have a neurogenic bladder or other disorder that, in the opinion of the investigator, may cause neurogenic bladder (including Parkinson's disease, multiple sclerosis, epilepsy, myasthenia gravis, movement disorders, spinal cord damage) Have pain or a pain disorder that, in the opinion of the investigator, would make it difficult to discriminate pelvic pain of bladder origin from the other pain Have any of the following central nervous system (CNS) conditions that in the opinion of the investigator would impact the subject's study participation due to their ability to follow the study protocol or bias study results, severe diagnosed: major depressive disorder, bipolar disorder, schizophrenia, general anxiety disorder, attention deficit disorder, obsessive compulsive disorder, or other major central nervous system disorder Have history of arrhythmias, conduction disturbances, or cardiac disease, or any coexisting medical condition that, in the opinion of the investigator, may be significant or interfere with study procedures or interpretation of study results Had bladder instillation therapy within 7 days prior to study entry or had a prior bladder instillation with heparin and lidocaine and did not respond Had an in-office cystoscopy within 7 days of study drug administration Had dilatation (hydrodistension) of bladder within 3 months of study entry Evidence or suspected presence of cancer detected during cystoscopy 7 days prior to or at time of initial screening (cystoscopy is not required for entry into the study) Has received any investigational drug or device within 30 days prior to screening Is currently enrolled in another investigational drug or device study Is unwilling or unable to abide by the requirements of the study Have an actively bleeding lesion or area in the bladder as detected by dipstick urinalysis and investigator assessment, immediately prior to randomization Are taking any of the following medications, which are inducers of CYP1A2 and/or CYP3A4: Phenytoin, Carbamazepine, St. John's Wort, Phenobarbital, Rifampin Have had any of the following: Bacterial cystitis within 30 days as demonstrated by a positive urine culture (≥ 105 bacteria per mL) History of pelvic irradiation or radiation cystitis History or presence of uterine, cervical, pelvic, rectal, ovarian, or vaginal cancer History of benign or malignant bladder tumors Current chemotherapy History or presence of tuberculous cystitis History or presence of chemical cystitis, including that due to cyclophosphamide History or presence of urinary schistosomiasis Bladder or ureteral calculi Clinically significant infectious vaginitis Currently uncontrolled genital herpes History or presence of urethral diverticulum Presence of bladder fistulae History of ketamine use
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Vaneltix Pharma, Inc.
Phone
732-247-0888
Email
info@vaneltix.com
Facility Information:
Facility Name
IC Study LLC
City
Escondido
State/Province
California
ZIP/Postal Code
92025
Country
United States
Individual Site Status
Recruiting
Facility Name
University of California Los Angeles Center for Women's Pelvic Health
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
The Continence Center Medical Group, Inc dba Southern California Continence Center
City
Newport Beach
State/Province
California
ZIP/Postal Code
92663
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
University of California San Diego Medical Center
City
San Diego
State/Province
California
ZIP/Postal Code
92103
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Scripps Clinic Carmel Valley
City
San Diego
State/Province
California
ZIP/Postal Code
92130
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Prestige Medical Group
City
Santa Ana
State/Province
California
ZIP/Postal Code
92705
Country
United States
Individual Site Status
Recruiting
Facility Name
Georgia Urology
City
Cartersville
State/Province
Georgia
ZIP/Postal Code
30120
Country
United States
Individual Site Status
Recruiting
Facility Name
Southern Clinical Research Associates LLC
City
Metairie
State/Province
Louisiana
ZIP/Postal Code
70001
Country
United States
Individual Site Status
Recruiting
Facility Name
Boston Urogynecology Associates
City
Cambridge
State/Province
Massachusetts
ZIP/Postal Code
02138
Country
United States
Individual Site Status
Not yet recruiting
Facility Name
Northwell Health
City
Lake Success
State/Province
New York
ZIP/Postal Code
11042
Country
United States
Individual Site Status
Not yet recruiting

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Safety and Efficacy Study of VNX001 Compared to Its Individual Components (Lidocaine and Heparin) or Placebo in Subjects With IC/BPS

We'll reach out to this number within 24 hrs